Abstracts tagged "Biologic drugs"

Abstract Number: 2473 • 2017 ACR/ARHP Annual Meeting
Sirukumab Subcutaneous Dose Regimens Maintain Clinical Response over Dosing Intervals in Rheumatoid Arthritis Patients: Results from a Phase 3 Study
David M. Brooks¹, Michael Plotnick², Nicola J. Williams³, Regina Kurrasch¹, Yanli Zhuang², Debra J. Tompson³, Benjamin Hsu² and Ravi Rao³, ¹GlaxoSmithKline, Collegeville, PA, ²Janssen Research & Development, LLC, Spring House, PA, ³GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, has demonstrated efficacy in rheumatoid arthritis (RA)…
Abstract Number: 631 • 2017 ACR/ARHP Annual Meeting
Predictors of Long-Term Retention of Methotrexate and Other Dmards with Golimumab in Rheumatoid Arthritis and Psoriatic Arthritis: An Analysis from a Prospective, Observational Registry
Derek Haaland¹, Anna Jaroszynska², B Haraoui³, Suneil Kapur⁴, Jacqueline Stewart⁵, Wojciech Olsynzynski⁶, Keltie Anderson⁷, Raman Rai⁸, Michael Starr⁹, Alexander Tsoukas¹⁰, Eliofotisti Psaradellis¹¹, Emmanouil Rampakakis¹¹, Cathy Tkaczyk¹², Allen J Lehman¹³, Francois Nantel¹² and Brendan Osborne¹², ¹Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, ²Private practice, Burlington, ON, Canada, ³Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁴University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ⁵Penticton Regional Hospital, Penticton, BC, Canada, ⁶University of Saskatchewan, Saskatoon, ON, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸Private Practice, Hamilton, ON, Canada, ⁹Rheumatology, McGill University, Pointe-Claire,, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have suggested that concomitant methotrexate therapy may increase the efficacy of biologic treatments. A scarcity of data exists on the benefits of…
Abstract Number: 2500 • 2017 ACR/ARHP Annual Meeting
Are Work Outcomes Improved in Axial Spondyloarthritis (axSpA) Patients with Biologic Therapy? Results from the British Society for Rheumatology Register
Gary J. Macfarlane, Gareth T. Jones and Joanna Shim, Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom
Background/Purpose: Patients with axial spondyloarthritis (axSpA) identify the ability to stay at work as a priority. Biologic therapy improves disease activity and quality of life…
Abstract Number: 636 • 2017 ACR/ARHP Annual Meeting
Effect of Adding MTX to TNF Inhibitors on Joint Severity Indices and Skin Scores in Psoriatic Arthritis: A Post-Hoc Meta-Analysis of Randomized, Controlled Trials
Rochelle Castillo¹, Khushboo Sheth² and Santhanam Lakshminarayanan³, ¹University of Connecticut, Farmington, CT, ²Rheumatology, Stanford University, Palo Alto, CA, ³Division of Rheumatology, University of Connecticut Health Center, Farmington, CT
Background/Purpose: Co-medication of MTX with TNF inhibitors (TNFi) has proven superior to TNFi monotherapy in improving clinical outcomes in patients with RA. Whether this holds…
Abstract Number: 2589 • 2017 ACR/ARHP Annual Meeting
Functional and Mechanistic Characterization of Anifrolumab, a Fully Human Monoclonal Antibody Targeting the Interferon Alpha Receptor 1 for the Treatment of SLE
Gary P. Sims¹, Jeffrey Riggs², Richard Hanna¹, Bhargavi Rajan³, Jodi Karnell¹, Kamelia Zerrouki¹, Divya Sagar¹, Inna Vainshtein³, Erika Farmer⁴, Meina Liang³, Miguel A. Sanjuan¹ and Roland Kolbeck¹, ¹Respiratory, Inflammation and Autoimmunity (RIA), MedImmune, LLC, Gaithersburg, MD, ²Respiratory, Inflammation and Autoimmunity (RIA), MedImmune LLC, Gaithersburg, MD, ³MedImmune, LLC, Mountain View, CA, ⁴Analytical Sciences, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Increased type I interferon (IFN) activity is associated with the pathogenesis of SLE. Anifrolumab, a fully human immunoglobulin (Ig) G1 κ monoclonal antibody in clinical…
Abstract Number: 842 • 2017 ACR/ARHP Annual Meeting
Risk of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologic Vs. Non-Biologic Dmards
Gulsen Ozen¹, Sofia Pedro², Bryant R. England³, Bella Mehta⁴, Frederick Wolfe² and Kaleb Michaud¹, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Rheumatology, Hospital for Special Surgery/Weill Cornell Medical College, New York, NY
Background/Purpose: Serious infections (SIs) are a major concern in RA patients, significantly contributing to increased mortality. We examined the SI risk associated with bDMARDs compared…
Abstract Number: 2592 • 2017 ACR/ARHP Annual Meeting
Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous Anifrolumab in Healthy Volunteers
Raj Tummala¹, Tomas Rouse², Anna Berglind² and Linda Santiago³, ¹AstraZeneca, Gaithersburg, MD, ²AstraZeneca, Gothenberg, Sweden, ³MedImmune, LLC, Mountain View, CA
Background/Purpose: Anifrolumab is a fully human anti–interferon-ɑ receptor 1 monoclonal antibody in Phase III development as an intravenous (IV) therapeutic for systemic lupus erythematosus (SLE).…
Abstract Number: 1451 • 2017 ACR/ARHP Annual Meeting
Starting of Biological Dmards May be Postponed in RA Patients with Multimorbidity: Single Centre Real Life Results
Berkan Armagan¹, Alper Sari¹, Abdulsamet Erden¹, Levent Kilic¹, Efe Cem Erdat², Omer Karadag³, Ali Akdogan¹, Sule Apras Bilgen³, Ihsan Ertenli³, Sedat Kiraz¹ and Umut Kalyoncu^1,3, ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Department of Internal Medicine, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: RA is a burdensome for most of the patients, comorbidities usually provide additional disadvantags the course of RA. The possible effects of comorbidities on…
Abstract Number: 27 • 2017 ACR/ARHP Annual Meeting
Effects of High Titers of Anti-Chimeric Antibodies Following Rituximab
Roberta Fenoglio¹, Laura Solfietti¹, Savino Sciascia² and Dario Roccatello¹, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: Monoclonal antibodies (MoAbs) are highly successful in treating various immunological disorders. The development of anti-drug antibodies (ADA) against the therapeutic MoAb is relatively common.…
Abstract Number: 1455 • 2017 ACR/ARHP Annual Meeting
Investigation of Poor Prognostic Factors Among Rheumatoid Arthritis Patients in Turkbio Registry
Nevsun Inanc¹, Zeynep Erturk¹, Gulsen Ozen¹, Ediz Dalkilic², Suleyman Serdar Koca³, Gerçek Can⁴, Ahmet Karatas⁵, Yavuz Pehlivan⁶, Ayten Yazici⁷, Ayse Cefle⁷, Servet Akar⁸, Soner Senel⁹, Burak Oz³, Nurullah Akkoc¹⁰, Haner Direskeneli¹ and Fatos Onen¹¹, ¹Rheumatology, Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ²Department of Internal Medicine, Division of Rheumatology, Uludag University, School of Medicine, Rheumatology, Bursa, Turkey, ³Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, ⁴Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ⁵Department of Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, ⁶Rheumatology, Uludag University, School of Medicine, Rheumatology, Bursa, Turkey, ⁷Rheumatology, Kocaeli University, School of Medicine, Rheumatology, Kocaeli, Turkey, ⁸Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ⁹Rheumatology, Kayseri Erciyes University, School of Medicine, Rheumatology, Kayseri, Turkey, ¹⁰Rheumatology, Private Practice, Rheumatology, İzmir, Turkey, ¹¹Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey
Background/Purpose: TURKBIO is the Turkish version of Danish DANBIO rheumatologic database which has been established in 2011.In 2016,the EULAR RA management guideline recommended assessment of…
Abstract Number: 196 • 2017 ACR/ARHP Annual Meeting
Patient Assistance Program Outcomes in a Community Clinic Setting
Stephanie Cerritos¹, Yanira Ruiz-Perdomo¹, Natalie Tobar¹, Ann Biehl² and James D. Katz³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Department of Pharmacy, National Institutes of Health Clinical Center, Bethesda, MD, ³National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD
Background/Purpose: Uninsured rheumatic disease patients are at risk for inadequate treatment due to issues with access to care, such as medication costs that average at…
Abstract Number: 1478 • 2017 ACR/ARHP Annual Meeting
Inadequate Clinical Response to Sirukumab, an Anti-IL-6 Monoclonal Antibody, Can be Predicted after a Single Dose of Treatment in Patients with Rheumatoid Arthritis
Shruti Daga¹, Daniel Aletaha², Benjamin Hsu³, Jennifer Gilbride⁴, Jacquie Christie⁵, Matthew Loza³, Bidisha Dasgupta³, Kim Campbell³, Kurt Brown⁶, Ravi Rao⁵ and Paul P. Tak⁵, ¹GlaxoSmithKline, Uxbridge, United Kingdom, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Sum of Squares Ltd, Hertfordshire, United Kingdom, ⁵GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, ⁶GlaxoSmithKline, Collegeville, PA
Background/Purpose: Response to therapy in rheumatoid arthritis (RA) is heterogeneous. Early identification of patients (pts) who are unlikely to achieve a meaningful clinical response may…
Abstract Number: 238 • 2017 ACR/ARHP Annual Meeting
Power Dopper Ultrasonography Detects Superior Efficacy of Non-TNF Biologics Compared to Cycling of TNF Inhibitors in RA Patients Inadequate Response to First TNF Inhibitors
Ayako Nishino^1,2,3, Shinya Kawashiri^2,3, Tamami Yoshitama², Nobutaka Eiraku², Naoki Matsuoka², Yukitaka Ueki², Akitomo Okada², Hiroaki Hamada², Toshihiko Hidaka², Shuji Nagano², Tomomi Tsuru², Keita Fujikawa², Yojiro Arinobu², Yoshifumi Tada², Yasuhiro Nagata¹ and Atsushi Kawakami^2,4, ¹Center for Comprehensive Community Care Education, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan, ³Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁴Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan
Background/Purpose: Efficacy of cycling of TNF inhibitors, judged by composite measures, is inferior to non-TNF biologics in patients with RA inadequate response to previous TNF…
Abstract Number: 1537 • 2017 ACR/ARHP Annual Meeting
Determinants of Patient-Reported Improvement after Administration of Biological Treatment in Axial Spondyloarthritis: A Cross-Sectional Study
Julianna Hirsch¹, Michal Nudel², Shira Ginsburg³, Haya Hussein³, Karina Zilber³, Lisa Kaly³, Doron Rimar³, Nina Boulman³, Abid Awisat³, Hily Wollach², Michael Rozenbaum³, Itzhak Rosner³ and Gleb Slobodin³, ¹Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Haifa, Israel, ²Mifrakim Tz'eirim, Haifa, Israel, ³Bnai-Zion Medical Center, Haifa, Israel
Background/Purpose: Efficacy of biological treatment in patients with axial spondyloarthritis (SpA) varies and is dependent on both disease-related and patient-related factors. The goal of this…
Abstract Number: 280 • 2017 ACR/ARHP Annual Meeting
Reasons Why Patients Failed Vaccinations Vs Influenza and Pneumococcus. Monocentric Cross-Sectional Study.
Maria Chiara Ditto¹, Alberto Batticciotto¹, Maria Chiara Gerardi¹, Federica Rigamonti², Rossella Talotta¹ and Piercarlo Sarzi-Puttini¹, ¹Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, ²Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy
Background/Purpose: immunosuppressive therapies and bDAMRDs expecially, increase the risk of infections. According to the EULAR guidelines, all patients affected by autoimmune/inflammatory diseases should receive vaccinations…

« Previous Page
1
…
3
4
5
6
7
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].